The influence of endocannabinoid receptor 1 gene variations on anthropometric and metabolic parameters of women with polycystic ovary syndrome

Endokrynologia Polska

Volumn 65, Issue 3, 2014, Pages 181-188

  Lenarcik Kabza, Agnieszka ^a   Łaczmański, Łukasz ^a   Milewicz, Andrzej ^a   Bidzińska Speichert, Bozena ^a   Pawlak, Maurycy ^a   Kolackov, Katarzyna ^a   Kuliczkowska Płaksej, Justyna ^a   Trzmiel Bira, Anna ^a   Brona, Anna ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

CNR1 polymorphism; Endocannabinoid system; Polycystic ovary syndrome

Indexed keywords

CANNABINOID 1 RECEPTOR; CHOLESTEROL; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CNR1 PROTEIN, HUMAN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY HEIGHT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HIP CIRCUMFERENCE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; PHYSICAL EXAMINATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BODY FAT DISTRIBUTION; CAUCASIAN; COMPLICATION; GENETICS; METABOLISM; OBESITY; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADULT; BODY FAT DISTRIBUTION; BODY MASS INDEX; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 84903604540     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2014.0025     Document Type: Article

References (34)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 863-861.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
3. Dunaif A, Graf M, Mandeli J et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65: 499-507.
4. Ehrmann DA, Barnes RB, Rosenfield RL et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-146.
5. Legro RS, Kunselman AR, Dodson WC et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-169.
6. Dahlgren E, Janson PO, Johansson S et al. Polycystic ovary syndrome and risk for myocardial infarction - evaluated from a risk factor model based on a prospective study of women. Acta Obstet Gynaecol Scand 1992; 71: 599-604.
7. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
8. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897-1899.
9. Kozakowski J, Zgliczyński W. Body composition, glucose metabolism markers and serum androgens - association in women with polycystic ovary syndrome. Endokrynol Pol 2013; 64: 94-100.
10. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. Endocrine Practice 2005; 11: 126-134.
11. Dokras A, Bochner M, Hollinrake E et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005; 106: 131-137.
12. Ehrmann DA, Liljenquist DR, Kasza K et al. PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 48-53.
13. Cota D, Marsicano G, Tschöp M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
14. Cote M, Matias I, Lemieux X et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007; 31: 692-699.
15. Blüher M, Engeli S, Klöting N et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
16. Annuzzi G, Piscitelli F, Di Marino L et al. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis 2010; 9: 43.
17. Baye TM, Zhang Y, Smith E et al. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics 2008; 9: 1647-1656.
18. Pagano C, Pilon C, Calcagno A et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylino-sitol 3-kinase and calcium dependent mechanisms. J Clin Endocrinol Metab 2007; 92: 4810-4819.
19. Jaeger J P, Mattevi VS, Callegari-Jacques SM et al. Cannabinoid type-1 gene polymorphisms are associated with central obesity in a Southern Brazilian population. Dis Markers 2008; 25: 67-74.
20. Russo P, Strazzullo P, Cappuccio FP et al. Genetic variations at the en-docannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab 2007; 92: 2382-2386.
21. Peeters A, Beckers S, Mertens I et al. The G1422A variant of the endocan-nabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine 2007; 31: 138-141.
22. Milewicz A, Tworowska-Bardzińska U, Jȩdrzejuk D et al. Are endocan-nabinoid type 1 receptor gene (CNR1) polymorphisms associated with obesity and metabolic syndrome in postmenopausal Polish women? Int J Obes (Lond) 2011; 35: 373-377.
23. Müller TD, Reichwald K, Wermter AK et al. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Mol Genet Metab 2007; 90: 429-434.
24. Lieb W, Manning AK, Florez JC et al. Variants in the CNR1 and the FAAH genes and adiposity traits in the community. Obesity (Silver Spring) 2009; 71: 755-760.
25. Zhuang M, Yang Y, Cao F et al. Associations of variants of CNR1 with obesity and obesity-related traits in Chinese women. Gene 2012; 495: 194-198.
26. de Luis DA, Pacheco D, Aller R et al. G 1359A polymorphism of the cannabinoid receptor gene (CNR1) and clinical results of biliopancreatic diversion. Eur Rev Med Pharmacol Sci 2010; 14: 197-201.
27. Wenger T, Ledent C, Csernus V et al. The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. Biochem Biophys Res Commun 2001; 284: 363-368
28. El-Talatini MR, Taylor AH, Elson JC et al. Localisation and function of the endocannabinoid system in the human ovary. PLoS One 2009; 4: e4579.
29. Łaczmańska I, Pesz K, Łaczmański Ł. Application of selected methods based on the polymerase chain reaction in medical molecular diagnostics. Adv Clin Exp Med 2009; 18: 85-92.
30. Łaczmański Ł, Milewicz A, Dunajska K et al. Endocannabinoid type 1 receptor gene (CNR1) polymorphisms (rs806381, rs10485170, rs6454674, rs 20232390 and cardiovascular risk factors in postmenopausal women. Gynecol Endocrinol 2011; 27: 1023-1027.
31. Benzinou M, Chevre JC, Ward KJ et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum Mol Genet 2008; 17: 1916-1921.
32. Hu WC, Feng P. G1359A polymorphism in the cannabinoid receptor-1 gene is associated with metabolic syndrome in the Chinese Han population. Arch Med Res 2010; 41: 378-382.
33. Liu R, Zhang Y. G1359A polymorphism in the cannabinoid receptor-1 gene is associated with coronary artery disease in the Chinese Han population. Clin Lab 2011; 57: 689-693.
34. Wang R, Hu W, Qiang L. G1359A polymorphism in the cannabinoid receptor-1 gene is associated with the presence of coronary artery disease in patients with type 2 diabetes. J Investig Med 2012; 60: 44-48.